The ovarian cancer market is advancing through precision medicine and novel therapeutic approaches. Leading companies including AstraZeneca, GSK, and Clovis Oncology are developing innovative PARP inhibitors, targeted agents, and combination therapies that enhance treatment efficacy and patient survival. Refined biomarker identification and personalized treatment protocols are optimizing clinical management for this challenging gynecologic cancer. View Full Analysis: https://shorturl.at/jU752